EGFR and head and neck squamous cell carcinoma: Although current evidence is limited in scale and fragmented, it can be concluded that immunotherapy for early-onset HNSCC patients should focus on targeting EGFR, inhibiting ECM remodeling and EMT, and paying attention to high P16 methylation and specific coexisting microbial infections.